Tesamorelin is a stabilized synthetic analog of growth-hormone-releasing hormone (GHRH) that acts one step upstream of growth hormone itself, prompting the pituitary to release its own stored hormone rather than replacing it. The published record describes a molecule that binds the GHRH receptor on pituitary somatotrophs, preserves the body's natural pulsatile release pattern, and drives the liver to produce IGF-1. Its single FDA-approved use is the reduction of excess visceral abdominal fat in people with HIV-associated lipodystrophy, and that human clinical evidence base does not extend to weight loss, bodybuilding, or anti-aging use.
Tesamorelin stimulates the pituitary to release growth hormone in its natural pulsatile pattern, raising IGF-1, and is FDA-approved only for reducing excess visceral fat in HIV-associated lipodystrophy.
The structure is built on the complete 44-amino-acid sequence of endogenous human GHRH(1-44), the naturally active form of the hypothalamic hormone, rather than a shortened fragment. The defining feature reported in the literature is a trans-3-hexenoic acid cap covalently attached to the N-terminal tyrosine, positioned exactly where the enzyme dipeptidyl peptidase-4 would otherwise cleave and inactivate native GHRH.
Tesamorelin is a peptide drug consisting of the full human GHRH(1-44) sequence capped at the N-terminus with a trans-3-hexenoyl group, supplied commercially as tesamorelin acetate.
The reported mechanism amplifies the body's own release signal at the very first step of the growth hormone axis rather than forcing an artificial pathway. Tesamorelin binds the GHRH receptor, a G-protein-coupled receptor on anterior-pituitary somatotrophs, and the literature describes the same intracellular cascade the hypothalamus normally drives with its own GHRH. Working against that push at every moment is somatostatin, the inhibitory hormone whose brake determines how much growth hormone actually reaches the bloodstream.
Tesamorelin activates the GHRH receptor's Gs-adenylate cyclase-cyclic AMP cascade in somatotrophs to release stored growth hormone, with the net output set by the balance against somatostatin's inhibitory tone.
Once circulating growth hormone rises, the published record describes much of the real work being carried out by insulin-like growth factor 1, produced mainly by the liver and locally in peripheral tissues. IGF-1 serves as the practical biomarker prescribers track because it integrates the pulsatile, hard-to-measure growth hormone response into a stable serum value. That monitoring matters because chronically elevated IGF-1 pushed above the age-adjusted normal range is a theoretical concern for tissue overgrowth.
IGF-1 is both the effector that carries much of growth hormone's downstream action and the serum biomarker prescribers monitor, and its own negative feedback on the pituitary limits how far tesamorelin can drive the axis.
The visceral-selective effect reported in the literature comes down to how growth hormone promotes fat breakdown and how differently the two fat depots respond to that signal. Growth hormone is lipolytic: it activates hormone-sensitive lipase and reduces lipoprotein lipase activity, tipping the balance toward mobilizing stored triglycerides as free fatty acids. Visceral adipose tissue is more richly perfused and more sensitive to that drive than subcutaneous fat, which is why the pivotal HIV-lipodystrophy trials showed the deep abdominal depot shrinking while subcutaneous fat and lean tissue were largely spared.
| Property | Visceral fat | Subcutaneous fat |
|---|---|---|
| Perfusion | Richly perfused | Less perfused |
| Lipolytic sensitivity | High | Lower |
| Response to tesamorelin | Preferentially mobilized | Largely spared |
| Trial reduction | Roughly 15 to 18 percent | Minimal change |
In the pivotal HIV-lipodystrophy trials, tesamorelin reduced visceral adipose tissue by roughly 15 to 18 percent over the initial treatment period while sparing subcutaneous fat and lean tissue, because visceral fat is more sensitive to growth-hormone-driven lipolysis.
Native GHRH is a fragile signaling molecule cleared from the bloodstream within minutes, mainly because dipeptidyl peptidase-4 clips the first two amino acids off its N-terminus and destroys its ability to activate the receptor. The published design solves this by capping that vulnerable end with a trans-3-hexenoyl group, physically shielding the cleavage site so the enzyme can no longer trim the peptide efficiently. The reported result is a plasma half-life long enough to reach the pituitary and act, which combined with the drug's reliance on the body's own pulsatile release is what makes a once-daily subcutaneous dose workable.
Capping the N-terminus with a trans-3-hexenoyl group blocks dipeptidyl peptidase-4 cleavage and extends the reported plasma half-life to roughly 26 to 38 minutes, long enough to support once-daily subcutaneous dosing.
The distinction reported in the literature is between amplifying a signal and bypassing the control system entirely. Because tesamorelin acts at the pituitary and tells the somatotrophs to release, the hormone comes out in the gland's own burst-and-trough rhythm, shaped by the ongoing interplay of GHRH signaling, somatostatin braking, and IGF-1 feedback. Injecting recombinant growth hormone directly does the opposite, dumping a bolus into the blood on the injection's schedule and producing a flat or spiked profile that ignores the body's timing and its feedback loops.
| Criteria | Tesamorelin | Direct GH injection |
|---|---|---|
| Site of action | Pituitary, upstream | Bloodstream, bypasses gland |
| Release profile | Native pulsatile rhythm | Flat or spiked bolus |
| Feedback intact | Yes, axis self-regulates | No, ignores feedback |
| Requires functional pituitary | Yes | No |
Because tesamorelin acts upstream at the pituitary, growth hormone is released in the body's native pulsatile rhythm under intact feedback, whereas direct recombinant growth hormone produces an unregulated bolus, though the upstream approach only works when the pituitary is functional and still stocked.
The literature describes tesamorelin's response as capped by the same regulatory machinery that governs natural growth hormone secretion, a consequence of working upstream rather than replacing the hormone. As growth hormone rises and the liver produces more IGF-1, that IGF-1 circulates back to suppress further release and to stimulate somatostatin, the inhibitory hormone that lowers the cyclic AMP signal tesamorelin is trying to raise. The reported effect is an axis that behaves like a thermostat rather than an open valve: the higher tesamorelin pushes, the harder the feedback pushes back.
The IGF-1 feedback loop, rising somatostatin tone, and potential receptor-level dampening together cap tesamorelin's effect within a physiological band, making sustained supraphysiologic growth hormone far harder to reach than with direct hormone dosing.
The FDA approval is written for a narrow, well-defined setting: reducing excess visceral abdominal fat in adults living with HIV who have lipodystrophy, a body-composition disorder linked to the infection and to earlier antiretroviral regimens. That accumulated visceral fat is the target because it carries cardiometabolic risk, and it is the depot most responsive to the growth-hormone-driven lipolysis tesamorelin sets in motion. The record is explicit that this is not an approval as a weight-loss drug, a bodybuilding aid, or an anti-aging therapy, and use outside the HIV-lipodystrophy indication is off-label and not supported by the approval.
Tesamorelin's FDA approval covers only the reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy, and its evidence base does not support weight-loss, bodybuilding, or anti-aging use.
The reported effect is reversible and depends entirely on continued dosing, because the drug transiently stimulates the pituitary rather than altering the gland permanently. After the last dose, growth hormone and IGF-1 levels fall back toward their untreated baseline over a span of days as the short-lived peptide clears and the daily stimulus disappears, with no evidence that a standard course leaves the axis lastingly suppressed. The clinically significant point in the literature is that the mobilized visceral fat tends to reaccumulate once therapy stops, since the underlying condition driving the fat distribution is still present.
After tesamorelin is stopped, growth hormone and IGF-1 return toward baseline within days with no reported lasting suppression, but the visceral-fat benefit is maintained only while dosing continues, making it an ongoing therapy for a chronic condition rather than a one-time fix.
Educational use only. This article describes what the published scientific and clinical literature reports about Tesamorelin. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
Talk to a licensed prescriber. Whether a treatment described here is appropriate for you depends on your medical history, your current medications, and the monitoring you may need. A licensed healthcare provider can evaluate your situation.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
